Despite knowledge and awareness of the role and potential consequences of increased hepcidin levels in oncological patients, there is a lack of studies focusing on both the potential diagnostic or therapeutic use of hepcidin and its role in the development of cancer-related anaemia, as well as how to incorporate this ready-to-use marker into the clinical field. This evidence concerns the gene HAMP and cancer.